Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.72 |
| ▸ | AHCY | P23526 | 10/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 2/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180861 | 0.89 | AHCY (0.74) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL28855667 | 0.86 | ADORA2A (0.97) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL904363 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL29496348 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL5810639 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL1393316 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| (S)-Dhpa SCHEMBL936286 | 0.83 | AHCY (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| (S)-Dhpa SCHEMBL936287 | 0.83 | AHCY (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| (S)-Dhpa SCHEMBL28605202 | 0.83 | AHCY (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL16504492 | 0.82 | ADORA2A (0.74) | ADORA2AADORA1AHCYALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169256-B2 | Artificial nucleic acids | ELITECHGROUP B.V. (NL) | 2015-10-27 | — | — | US | disclosed |
| US-20140275508-A1 | ARTIFICIAL NUCLEIC ACIDS | ELITECH HOLDING B.V. (NL) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275508-A1 | ARTIFICIAL NUCLEIC ACIDS | NSUN2, POLRMT, NSUN3 | ADORA2A 339/4885ADORA1 386/4885AHCY 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.